At PharmSci 360, Insilica CEO Thomas Luechtefeld will present on auditable agentic AI systems and how they are expanding computational toxicology beyond single predictive models.
|Articles|July 1, 2015
- BioPharm International-07-01-2015
- Volume 28
- Issue 7
High-Pressure Homogenizer Reduces Maintenance
GEA’s Panther NS3006L high-pressure homogenizer is a standalone unit designed to reduce particle size to nanometer ranges.
Advertisement
GEA’s Panther NS3006L high-pressure homogenizer is a standalone unit designed to reduce particle size to nanometer ranges for injectable drugs. Continuous operation allows up to 1500 bar for limited productions in pilot plants. The ergonomic unit is made from Super Duplex SS alloy, fitted with wear-resistant parts, and has an analog pressure gauge in a sanitary design with built-in pulsation damper. The unit also has a rupture type, sharp-edge homogenizing valve (Stellite) in special abrasion and wear-resistant material. GEA Niro Soavi
Articles in this issue
over 11 years ago
Risk Assessment and Mitigation in Biopharmaceutical Manufacturingover 11 years ago
Using Single-Use Technologies in Downstream Processingover 11 years ago
Aseptic Processing: Keeping it Safeover 11 years ago
Viral Detection Technologies Must Continue to Evolveover 11 years ago
Optimizing the Delivery of Cell-Culture Additivesover 11 years ago
Unravelling the Complexity of EU’s ATMP Regulatory Frameworkover 11 years ago
For Big Ideas, Big Action Is Neededover 11 years ago
CDMOs Cautiously Address Expansionover 11 years ago
Breakthrough Drugs Raise Development and Production ChallengesAdvertisement
Related to this article
BMS's Dr Nathan Pennell outlines how biomarker testing barriers and trial diversity affect patient access to targeted oncology drugs.
Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
Advertisement
Advertisement
Trending on BioPharm International
1
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
2
FDA Approves On-Body Injector Induction for Skyrizi in Crohn's Disease
3
Zymeworks Licenses DLL3-Targeted Trispecific T-Cell Engager ZW209 to Roche in Deal Worth Up to $813 Million
4
Gilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion
5